-

Neurenati Therapeutics Strengthens Its Board of Directors With the Appointment of Dr. Marielle Cohard-Radice

MONTREAL--(BUSINESS WIRE)--Neurenati Therapeutics, a pediatric rare diseases-focused company, is delighted to announce the appointment of a highly-experienced executive in the pharma industry as an independent board member.

Dr Marielle Cohard-Radice is a gastroenterologist who held various executive positions in several therapeutic areas over three decades. She is currently Executive Vice-president, Global Head of Development Operations at Daiichi Sankyo.

“Marielle’s role will be key in refining our clinical development strategy and maximize our development success rate. Welcome on the board of directors,” added Maxime Ranger, CEO of Neurenati.

“Newborns with Hirschsprung's disease deserve a treatment option to avoid surgery. Preclinical efficacy data showed that NEU-001 hold promise in regenerating the enteric nervous system of these children. Looking forward to supporting Neurenati in its efforts,” said Dr. Cohard-Radice

Both independent board members, Dr Alexandre Lebeaut and Dr Marielle Cohard-Radice will assist Neurenati to create its scientific and clinical advisory board in upcoming months.

NEW MANAGEMENT TEAM MEMBER

Neurenati also announces the appointment of Dr Marie-Eve Bordeleau as Senior Director, Preclinical development. Prior to joining Neurenati’s team, Dr Bordeleau was Deputy Director of the Molecular genetics of stem cells research unit, IRIC, Université de Montréal, under the direction of Dr. Guy Sauvageau. She will be responsible for the entire preclinical program in addition to overseeing the manufacturing of NEU-001.

ABOUT NEURENATI

Neurenati Therapeutics is a Québec-based biotech company dedicated to developing therapies for rare diseases. The first technology targets Hirschsprung disease (HSCR), a life-threatening gastrointestinal (GI) birth defect characterized by the lack of nerves in parts of the lower GI tract. Neurenati proposes an innovative therapy involving growth factor to treat newborns with HSCR, thereby averting the need for surgery and associated complications.

Contacts

MEDIA CONTACT
Maxime Ranger, PhD MBA
President and CEO
Neurenati Therapeutics Inc
E: maxime@neurenati.com
T: +1.514.825.9035

Industry:

Neurenati Therapeutics

Release Versions
EnglishFrench

Contacts

MEDIA CONTACT
Maxime Ranger, PhD MBA
President and CEO
Neurenati Therapeutics Inc
E: maxime@neurenati.com
T: +1.514.825.9035

More News From Neurenati Therapeutics

The US FDA Grants Both Orphan Drug and Rare Pediatric Disease Designations to NEU-001 of Neurenati for the Treatment of Hirschsprung Disease

MONTREAL--(BUSINESS WIRE)--Neurenati Therapeutics Inc., a biotech company focused on rare pediatric diseases, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted both Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) to NEU-001, a novel combination therapy utilizing a neurotrophic growth factor, for the treatment of Hirschsprung disease (HD). NEU-001 is a first-in-class, once-in-a-lifetime treatment administered intrarectally to regenera...

Neurenati Therapeutics Concludes a Second Seed Financing of 1.7 Million $ With the Support of Impulsion PME

MONTREAL--(BUSINESS WIRE)--Neurenati Therapeutics is delighted to announce the Quebec Government’s investment of $1.38 million via its Impulsion PME program, for which Investissement Québec acts as agent. With the addition of angel investors, this brings the total funding to $2.9 million needed for Neurenati to effectively advance NEU-001 toward clinical trials. NEU-001 is a proposed first-in-class therapy to treat Hirschsprung's disease, a rare gastrointestinal disease affecting approximately...

Neurenati Therapeutics Concludes a 1.2 Million $ Seed Financing Round to Develop NEU-001 as a Promising Therapy for Hirschsprung Disease

MONTREAL--(BUSINESS WIRE)--Neurenati Therapeutics is delighted to announce the successful closing of its seed funding round, securing 1.2 million $ from Genson Capital, on the 2024 Rare Disease Day. Neurenati, a Québec-based biotech company, focuses on the development of various rare diseases therapies, including pediatric conditions. Combined with the CQDM-SynergiQc grant, this financing will accelerate the development of NEU-001, a first-in-class therapy to Hirschsprung’s disease (HSCR), a ra...
Back to Newsroom